Axovia Therapeutics
Axovia Therapeutics is a biotechnology company developing gene therapies to treat inherited retinal diseases. The company is advancing AXV-101, an investigational gene therapy targeting vision loss associated with Bardet-Biedl Syndrome 1 (BBS1), toward first-in-human clinical trials.
Leadership & Board
- Current Number of Employees
- 6
- Current LinkedIn Followers
- 3,112
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $1M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $1M
- Latest Funding Round
- Investment
- Post-Money Valuation
- ―
Employee Trend
Axovia Therapeutics had 6 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
6Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Axovia Therapeutics had 3,112 followers as of October 12, 2026. The number of followers increased by 7 (0.23%) week-over-week.
3,112Latest Followers Count
7(0.23%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 06, 2026 | Investment | $1.10M | ― |
Similar Companies
A snapshot of private companies similar to Axovia Therapeutics, helping you discover and navigate related company profiles.
